BRPI0410055A - antagonistas de receptor de glutamato como neuroprotetores - Google Patents

antagonistas de receptor de glutamato como neuroprotetores

Info

Publication number
BRPI0410055A
BRPI0410055A BRPI0410055-7A BRPI0410055A BRPI0410055A BR PI0410055 A BRPI0410055 A BR PI0410055A BR PI0410055 A BRPI0410055 A BR PI0410055A BR PI0410055 A BRPI0410055 A BR PI0410055A
Authority
BR
Brazil
Prior art keywords
glutamate receptor
neuroprotectors
receptor antagonists
glutamate
relates
Prior art date
Application number
BRPI0410055-7A
Other languages
English (en)
Inventor
Wolfgang S Hngen
Original Assignee
Paion Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paion Deutschland Gmbh filed Critical Paion Deutschland Gmbh
Publication of BRPI0410055A publication Critical patent/BRPI0410055A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"ANTAGONISTAS DE RECEPTOR DE GLUTAMATO COMO NEUROPROTETORES". A invenção refere-se ao uso de um inibidor de ativação mediada por t-PA do receptor de glutamato, preferivelmente do tipo NMDA, como neuroprotetor.
BRPI0410055-7A 2003-05-05 2004-05-05 antagonistas de receptor de glutamato como neuroprotetores BRPI0410055A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10337098 2003-05-05
DE10320336 2003-05-06
DE10352333 2003-11-06
PCT/EP2004/004776 WO2004098635A1 (de) 2003-05-05 2004-05-05 Glutamat-rezeptor-antagonisten als neuroprotektiva

Publications (1)

Publication Number Publication Date
BRPI0410055A true BRPI0410055A (pt) 2006-04-25

Family

ID=33436868

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410055-7A BRPI0410055A (pt) 2003-05-05 2004-05-05 antagonistas de receptor de glutamato como neuroprotetores

Country Status (12)

Country Link
US (1) US20080213244A1 (pt)
EP (1) EP1622640A1 (pt)
JP (1) JP2006525277A (pt)
KR (1) KR20060015721A (pt)
AU (1) AU2004237407A1 (pt)
BR (1) BRPI0410055A (pt)
CA (1) CA2524342A1 (pt)
EA (1) EA200501753A1 (pt)
HR (1) HRP20050898A2 (pt)
MX (1) MXPA05011762A (pt)
NO (1) NO20055725D0 (pt)
WO (1) WO2004098635A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
MX2007016439A (es) * 2005-06-24 2008-03-04 Wilex Ag Uso de inhibidores de urocinasa para el tratamiento y/o prevencion de enfermedades neuropatologicas.
TWI482628B (zh) * 2007-10-18 2015-05-01 Lundbeck & Co As H 新穎之血栓溶解病患次群

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786187A (en) * 1995-09-21 1998-07-28 The Research Foundation Of State University Of New York Method for reducing neuronal degeneration associated with seizure
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall

Also Published As

Publication number Publication date
NO20055725L (no) 2005-12-02
AU2004237407A1 (en) 2004-11-18
MXPA05011762A (es) 2006-03-30
EP1622640A1 (de) 2006-02-08
NO20055725D0 (no) 2005-12-02
WO2004098635A1 (de) 2004-11-18
CA2524342A1 (en) 2004-11-18
US20080213244A1 (en) 2008-09-04
EA200501753A1 (ru) 2006-04-28
HRP20050898A2 (en) 2007-03-31
KR20060015721A (ko) 2006-02-20
JP2006525277A (ja) 2006-11-09

Similar Documents

Publication Publication Date Title
ZA200700616B (en) Modified pyrimidine glucocorticoid receptor modulatore
DK1337518T3 (da) Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
BR0209242A (pt) Aminopolidiorganossiloxanos amido-funcionais
TNSN07196A1 (en) Potentiators of glutamate receptors
GB0115862D0 (en) Compounds
PT1444215E (pt) Derivados de 1,2,4-triadiazolio como moduladores do receptor de melanocortina
JO2578B1 (en) Compounds Theophene benzimidazole
SMP200600024B (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
CR7728A (es) Nuevas quinazolinas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
TW200612945A (en) Aerosol suspension formulations containing TG 227 ea as propellant
DE602007004999D1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
BRPI0112375B8 (pt) aplidinas como derivados antitumorais
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
EA200501753A1 (ru) Антагонисты глутаматного рецептора в качестве нейрозащитных средств
MX2008000874A (es) Metodos y composiciones para anticoncepcion de emergencia utilizando antagonistas del receptor de endotelina.
MXPA05012279A (es) Derivados de bencil sulfonamida.
AU2003266093A1 (en) Cyclooct-(en-)yl derivatives for use as fragrances
ATE275551T1 (de) Halogenpyrimidine
UY27183A1 (es) -novedosos derivados de pirimidinona sustituidos que se combinan con receptores de integrina, su preparación y su uso.
UA89789C2 (ru) Суспензионные композиции, которые распыливаются в виде аэрозоля, с tg 227 еа или tg 134а в качестве пропеллента
YU39603A (sh) Jedinjenja piperazinilpirazina kao antagonisti serotonin 5-ht2 receptora
ITVR20020030A0 (it) Miscela per polvere di saldatura, nonche procedimento per l'impiego di detta miscela.
DOP2005000258A (es) Profarmaco de amina de gencitabina, composiciones y uso del mismo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.